SCHEDULE: Barclays Discloses 6.88% Stake in Ironwood Pharma
Beneficial Ownership Disclosure
Barclays PLC has disclosed a beneficial ownership of 6.88% of Ironwood Pharmaceuticals Inc.'s common stock, totaling 11,133,857 shares.
Summary
- Barclays PLC has reported beneficial ownership of 11,133,857 shares of Ironwood Pharmaceuticals Inc. common stock.
- This stake represents 6.88% of the total class of securities.
- Barclays PLC holds sole voting power and sole dispositive power over all 11,133,857 shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of a significant institutional ownership stake, which is generally neutral in terms of company operations but can be viewed as a vote of confidence by a major financial institution.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment by Barclays PLC in Ironwood Pharmaceuticals Inc., a common practice where large financial institutions acquire substantial, non-controlling stakes in publicly traded companies, particularly within the pharmaceutical sector, for investment purposes.
Stakeholder Impact
- Shareholders may perceive increased institutional interest and confidence in Ironwood Pharmaceuticals Inc. due to Barclays PLC's significant stake.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement |
| 08/12/2025 | Signature date of the filing by Ramya Rao, Director of Barclays PLC |
Keywords
Ironwood Pharmaceuticals, Barclays, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceutical, Institutional Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.